Shots:

• The company has applied for emergency use authorization to the DCGI for ZyCoV-D- which is the world's first plasmid DNA vaccine for COVID-19
• Zydus conducted a clinical trial for its ZyCoV-D in the adolescent population aged 12-18yrs. in India over 50 centers. The vaccine is safe and well-tolerated and showed 66% efficacy for symptomatic RT-PCR positive cases.
• The vaccine reaffirms its efficacy against the new mutant strains especially the delta variant. ZyCoV-D is a three-dose- intradermal vaccine- and is needle-free- leading to a reduction in any side effects. The company plans to manufacture 10-12 crore doses annually

  | Ref: Zydus | Image: PR Newswire